Sanofi Consumer Healthcare India Limited (SANOFICONR) Q2 2025 earnings summary

Executive summary

• Reported 28% year-on-year revenue growth in Q2 2025, reaching ₹2,209 million, driven by export operations and successful product launches.

• Profit after tax for Q2 2025 rose 21% sequentially to ₹607 million.

• Relaunch of Depura 60k and Combiflam Suspension, and launch of Allegra D contributed to performance.

• Commenced export operations, expanding international market reach.

Financial highlights

• Q2 2025 revenue: ₹2,209 million, up 28% year-over-year and 27.5% from Q1 2025.

• H1 2025 revenue: ₹3,935 million.

• Q2 2025 profit after tax: ₹606 million; H1 2025 PAT: ₹1,107 million.

• Exceptional gain of ₹66 million in Q2 2025 from reversal of excess demerger-related provisions.

Outlook and guidance

• Focus remains on innovation, portfolio expansion, and making self-care more accessible.

• Continued efforts to relaunch previously recalled products and strengthen legacy brands.